FAQ

Cerus

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2016
01220012016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Comparison of hepatitis E virus nucleic acid test screening platforms and RNA prevalence in French blood donors.
Comparison of hepatitis E virus nucleic acid test screening platforms and RNA prevalence in French blood donors Hepatitis E virus… (More)
  • table 1
Is this relevant?
2016
2016
Metabolomic profiling highlights oxidative damages in platelet concentrates treated for pathogen inactivation and shows protective role of urate
Research in transfusion medicine is motivated by the desire to deliver the most-compatible and most-efficient blood product to… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step.
BACKGROUND The Intercept Blood SystemTM (Cerus) is used to inactivate pathogens in platelet concentrates (PC). The aim of this… (More)
  • table I
  • figure 1
  • table II
  • figure 2
  • figure 3
Is this relevant?
2015
2015
Biomedical briefing
  • Nature Medicine
  • 2015
Blood boost On 19 December, the US Food and Drug Administration (FDA) in Silver Spring, Maryland, approved the first system aimed… (More)
Is this relevant?
2013
2013
Biological response modifiers in photochemically pathogen-reduced versus untreated apheresis platelet concentrates.
BACKGROUND Lipids and other biologically active substances accumulate in platelet concentrates (PCs) during storage. Some of… (More)
Is this relevant?
2012
2012
Amotosalen
  • BioDrugs
  • 2012
 
  • table I
  • table II
Is this relevant?
Review
2009
Review
2009
Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products
The irradiation of cellular blood components to prevent transfusion-associated (TA)-GVHD is an established practice in the… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2003
2003
Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV.
Trypanosoma cruzi, the protozoan pathogen that causes Chagas' disease, can be found in the blood of infected individuals for… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
Is this relevant?
2003
2003
Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
  • BioDrugs : clinical immunotherapeutics…
  • 2003
Adis CommentsCerus Corporation is developing a variety of pathogen-inactivation systems, based on its Helinx technology. Three of… (More)
Is this relevant?
Review
2001
Review
2001
Design of clinical trials to evaluate the efficacy of platelet transfusion: the euroSPRITE trial for components treated with Helinx technology.
Methods of collection, preparation, and transfusion of platelet components have evolved markedly since the introduction of modern… (More)
Is this relevant?